You are here
Peer-reviewed articles on preclinical research in Melanoma
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.
Corrie PG, Marshall A, Dunn JA, Middleton MR, Nathan PD, Gore M, Davidson N, Nicholson S, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Young G, Lorigan P.Lancet Oncol. 2014 May;15(6):620-30. Epub 2014 Apr 15.
The effectiveness of anti-angiogenic factors in the treatment of melanoma is currently the subject of many clinical trials. Especially the activity of bevacizumab in the treatment of patients with advanced melanoma looks promising. The AVAST-M trial is a phase III trial designed to evaluate the efficacy of adjuvant treatment with bevacizumab in patients at high risk of recurrence. The primary end point was the OS. The 1343 patients enrolled were randomized to receive bevacizumab 7.5 mg every 3 weeks for a year or to observation. The results of the interim analysis showed no benefit in terms of OS, and neither of distant metastasis-free interval. A statistically significant difference was found in terms of disease-free interval for patients in the bevacizumab group compared with those in the observation group (HR 0.83, 95% CI 0.70 -0 • 98, p = 0.03). Treatment with bevacizumab was well tolerated. We will need to wait for the results of the follow-up to 5 years to identify an effect on the OS.
Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma
Sara Harcharik, Sebastian Bernardo, Marina Moskalenko, Michael Pan, Meera Sivendran, Heather Bell, Lawrence D. Hall, Mireia Castillo-Martín, Kelly Fox, Carlos Cordon-Cardo, Rui Chang, Shanthi Sivendran, Robert G. Phelps, Yvonne SaengerJournal of the American Academy of Dermatology, In Press, March 2014
Editors' comments: Dr. James Larkin
Harcharik and colleagues report an association of CD2 positivity and risk of relapse in a retrospective cohort of 90 stage 2 and 3 melanoma patients over almost 10 years. This association does not define the role of CD2 in disease progression but is of interest and requires investigation in independent datasets.
Katharina Limm, Corinna Ott, Susanne Wallner, Daniel W. Mueller, Peter Oefner, Claus Hellerbrand, Anja-Katrin Bosserhoff
European Journal of Cancer, 6, 49, pages 1305 - 1313
Combined stimulation of TLR9 and 4.1BB augments Trp2 peptide vaccine-mediated melanoma rejection by increasing Ag-specific CTL activity and infiltration into tumor sites
Jeong-Im Sin, Ha Kim, Euri Ahn, Yong Hwan Jeon, Won Sun Park, Sang-Yeul Lee, Byungsuk Kwon
Cancer Letters, 2, 330, pages 190 - 199
R.L. Morton, L. Rychetnik, K. McCaffery, J.F. Thompson, L. Irwig
European Journal of Surgical Oncology (EJSO), 3, 39, pages 297 - 303
Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study
Reinhard Dummer, Simone M. Goldinger, Christian P. Turtschi, Nina B. Eggmann, Olivier Michielin, Lada Mitchell, Luisa Veronese, Paul René Hilfiker, Lea Felderer, Jeannine D. Rinderknecht
European Journal of Cancer
Klaus J. Busam MD
Seminars in Diagnostic Pathology, 4, 30, pages 362 - 374
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
James Larkin, Michele Del Vecchio, Paolo A Ascierto, Ivana Krajsova, Jacob Schachter, Bart Neyns, Enrique Espinosa, Claus Garbe, Vanna Chiarion Sileni, Helen Gogas, Wilson H Miller, Mario Mandalà, Geke A P Hospers, Ana Arance, Paola Queirolo, Axel HauschiThe Lancet Oncology, Early Online Publication, 27 February 2014
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.
Ascierto PA, Simeone E, Sileni VC, Vecchio MD, Marchetti P, Cappellini GC,Ridolfi R, de Rosa F, Cognetti F, Ferraresi V, Testori A, Queirolo P, BernengoMG, Guida M, Galli L, Mandalà M, Cimminiello C, Rinaldi G, Carnevale-Schianca F, Maio M.Cancer Invest. 2014 Jan 31. [Epub ahead of print]
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients
Simone M. Goldinger, Lisa Zimmer, Carsten Schulz, Selma Ugurel, Christoph Hoeller, Katharina C. Kaehler, Dirk Schadendorf, Jessica C. Hassel, Juergen Becker, Axel Hauschild, Reinhard Dummer, on behalf of, Dermatology Cooperative Oncology Group (DeCOG).
European Journal of Cancer